12 completed, 2 terminated, 1 active not recruiting. 11 Phase 2, 1 Early Phase 1, 1 Not applicable, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 10, Active not recruiting 1 |
| Early Phase 1 | 1 | Terminated 1 |
| Not applicable | 1 | Terminated 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Iris Melanoma: new trials by email Literature Review of Iris Melanoma trials Research Report on Iris Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma TBio-4101, Cyclophosphamide, Fludarabine - Metastatic Melanoma, Unresectable Melanoma | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 17 | 2022-11-22 | 2026-04-02 |
| Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma Sunitinib, Valproic Acid, Sunitinib Malate - Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size | Phase 2 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 210 | 2014-11-19 | 2026-10-22 |
| Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases External Beam Radiation Therapy, Laboratory Biomarker Analysis - Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma | Not applicable | Terminated | Jonsson Comprehensive Cancer Center | 2 | 2014-10-01 | 2020-07-24 |
| Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases ipilimumab, yttrium Y 90 glass microspheres, laboratory biomarker analysis - Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size | Early Phase 1 | Terminated | Case Comprehensive Cancer Center | 6 | 2012-12-01 | 2016-03-10 |
| Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye Cixutumumab, Laboratory biomarker analysis - Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size | Phase 2 | Completed | National Cancer Institute (NCI) | 18 | 2011-08-01 | 2020-02-19 |
| Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye carboplatin, paclitaxel, sorafenib tosylate - Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 25 | 2011-02-01 | 2014-07-31 |
| Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye Dacarbazine, Laboratory Biomarker Analysis, Quality-of-Life Assessment - Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 120 | 2010-06-01 | 2017-07-26 |
| Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance recombinant interferon alfa-2b, dacarbazine, laboratory biomarker analysis - Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size | Phase 2 | Completed | Case Comprehensive Cancer Center | 38 | 2009-11-11 | 2019-02-26 |
| VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery ziv-aflibercept, pharmacological study - Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 41 | 2007-06-01 | 2018-05-24 |
| AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma cediranib maleate - Acral Lentiginous Malignant Melanoma, Ciliary Body and Choroid Melanoma, Medium/Large Size | Phase 2 | Completed | National Cancer Institute (NCI) | 24 | 2006-01-01 | 2018-08-27 |
| Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma carboplatin, paclitaxel, bortezomib - Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 36 | 2005-10-01 | 2013-03-05 |
| Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma vorinostat - Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 32 | 2005-09-01 | 2019-01-29 |
| Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma tyrosinase peptide, gp100 antigen, MART-1 antigen - Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 40 | 2004-06-01 | 2015-04-15 |
| Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma gp100 antigen, tyrosinase peptide, recombinant MAGE-3.1 antigen - Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size | Phase 2 | Completed | University of Southern California | 42 | 2004-05-01 | 2014-05-22 |
| Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery Laboratory Biomarker Analysis, Placebo, Sargramostim - Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma | Phase 3 | Completed | National Cancer Institute (NCI) | 815 | 2000-02-23 | 2026-06-24 |
Uveal Melanoma (15) · Melanoma (8)
Eye Diseases (15) · Eye Neoplasms (15) · Neoplasms (15) · Neoplasms by Histologic Type (15) · Neoplasms by Site (15) · Neoplasms, Germ Cell and Embryonal (15) · Neoplasms, Nerve Tissue (15) · Neuroectodermal Tumors (15) · Neuroendocrine Tumors (15) · Nevi and Melanomas (15) · Uveal Diseases (15) · Uveal Neoplasms (15) · Skin Diseases (8) · Skin Neoplasms (8) · Skin and Connective Tissue Diseases (8)
Carboplatin (2) · Dacarbazine (2) · Paclitaxel (2) · incomplete Freund's adjuvant (2) · montanide ISA 51 (2) · sargramostim (2) · AZD 6244 (1) · Bortezomib (1) · CTLA-4 Antigen (1) · Colony-Stimulating Factors (1) · Cyclophosphamide (1) · Epilim (1) · Interferon alpha-2 (1) · Interleukin-2 (1) · Introns (1)
National Cancer Institute (NCI) (9) · Case Comprehensive Cancer Center (2) · H. Lee Moffitt Cancer Center and Research Institute (1) · Jonsson Comprehensive Cancer Center (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · University of Southern California (1)
United States (14) · Canada (3)
Jeffrey Weber (2) · Ahmad Tarhini (1) · Amod Sarnaik, MD (1) · Ana Aparicio (1) · David H Lawson (1) · Elaine McWhirter (1) · Gary Croghan (1) · Michael McNamara, MD (1) · Mitchell Kamrava (1) · Naomi Balzer-Haas (1) · Paul Chapman (1) · Sapna Patel (1) · Takami Sato, MD (1) · Yogen Saunthararajah, MD (1)
PMID 23077008, PMID 23226204, PMID 24464266, PMID 24938562, PMID 26351350, PMID 27921276, PMID 31371315
N01CM62203 (2), N01CM00039 (1), N01CM00070 (1), N01CM00071 (1), N01CM00099 (1), N01CM00100 (1), N01CM62201 (1), N01CM62205 (1), N01CM62206 (1), N01CM62208 (1), N01CM62209 (1), P30CA008748 (1), P30CA016672 (1), P30CA033572 (1), U01CA132123 (1)